Tag Archives: FDA

Orphan Drugs: Making Rare Diseases Rarer

Panel

A panel at the BIO CEO & Investor Conference provided an analysis of the thriving orphan drug market opportunity featuring industry, clinical and regulatory experts specializing in rare diseases. The signing of FDASIA by President Obama in July reinforces the country’s commitment to fostering innovation for rare diseases. With a record 460 medicines in late-stage clinical trials, biopharmaceutical companies have embraced rare disease medicine and are rapidly developing the pipeline with hopes of achieving the Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Simpson Bowles Keynote to Address Debt, Taxes, Government Services and Politics

Jim Greenwood

I was recently asked what the single biggest threat to the biotechnology industry is today.  My answer was immediate – the biggest threat to biotech innovation is the unsustainable mismatch of spending and revenue in the U.S. federal budget. The enormous national debt and the huge annual budget deficits that feed it endanger America’s entire economic future – but the nation’s dire fiscal situation is particularly threatening to our industry. Part of the reason for Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , ,

California Biomedical Companies Cite Lack Of Funding As Major Concern

Investment

As I have mentioned in past blog posts, the U.S. bioscience industry has demonstrated stability through turbulent economic times. While not immune from the recession, this industry generally fared much better than the overall economy and has remained a net a job generator. In April of 2012, the White House released the National Bioeconomy Blueprint noting that bioscience industries are “a large and rapidly growing segment of the world economy that provides substantial public benefit.” Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

FDASIA: A Step Forward for Patients

fdasia-panel

Earlier this year, Congress passed and President Obama signed the FDA Safety and Innovation Act (FDASIA) which included a re-authorization of the Prescription Drug User Fee Act (PDUFA). PDUFA provides essential funding to the FDA by authorizing the agency to charge user fees to companies seeking to have products reviewed. Originally enacted in 1992, it must be reauthorized every 5 years. Sara Radcliffe, executive vice president of health at BIO, moderated a panel of experts and advocates Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,

Public Health at Risk: Don’t Cut Programs that Work

cliff

In order to avoid the “fiscal cliff,” the Congress must compromise and protect our economic future by cutting costs and raising revenue, without compromising our nation’s support for critical government programs. Programs vital to the health of our nation – quite literally – should not suffer dramatic cuts. Making cuts to these programs could actually cost our nation more in the long run. The unintended consequences could impact our economic health, as well as our Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,